Results From Halted Islatravir Antiretroviral Trial

Recruitment stopped on the phase 3 trial of the once-daily oral drug islatravir in combination with doravirine, but the study of the investigational new option for HIV continued for the full 48 weeks.
Medscape Medical News

source https://www.medscape.com/viewarticle/995172?src=rss

Comments

Popular posts from this blog

RA and RA-ILD Linked to Higher Lung Cancer Risk

New AAFP practice guideline sets blood pressure targets for adults with hypertension

Heart Failure Care Outside of ICU Can Lower Cost